Terry Mary Beth, Zhang Fang Fang, Kabat Geoffrey, Britton Julie A, Teitelbaum Susan L, Neugut Alfred I, Gammon Marilie D
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Ann Epidemiol. 2006 Mar;16(3):230-40. doi: 10.1016/j.annepidem.2005.06.048. Epub 2005 Oct 17.
Moderate alcohol intake of one to two drinks per day has been consistently associated with a 30-50% increase in breast cancer. Despite the consistency in the overall association, several important questions remain, including whether the association between alcohol intake and breast cancer risk is affected by the timing of alcohol exposure, modified by other risk factors such as body mass index (BMI), menopausal status, and hormone replacement therapy (HRT), or more pronounced among hormone receptor positive tumors or invasive rather than in situ disease.
To address these questions, we conducted a large population-based study (1508 cases and 1556 controls) that collected detailed information on alcohol and other exposures throughout the lifecourse.
Consumption of 15-30 grams/day (approximately one to two drinks) throughout life was associated with a modest 33% increase in risk (odds ratio [OR] = 1.33, 95% confidence interval (CI) = 1.01-1.74), but heavier consumption (> or = 30 grams per day) was not. Risk did not vary with alcohol type (beer, wine, or hard liquor) or by patterns of use, such as recent use, intake prior to age 20 years, or whether use began at an early age. The association with lifetime intake was limited to women with a BMI < 25 (OR = 2.13, 95% CI = 1.29-3.54). Alcohol consumption of approximately one drink per day was associated with estrogen receptor positive tumors among women with a BMI < 25, but not among women BMI > or = 25. Also, the elevated OR was observed only among women diagnosed with invasive (OR = 1.56, 95% CI = 1.11-2.18), but not in situ breast tumors.
These data give added support that moderate alcohol consumption over the life course increases breast cancer risk, particularly among women with low BMI and those diagnosed with estrogen receptor positive tumors or with invasive rather than in situ disease. Risk is confined to moderate intake and does not vary with the timing of use, with heavier doses, or with the type of alcohol consumed.
每天适度饮用一到两杯酒一直与乳腺癌风险增加30%至50%相关。尽管总体关联具有一致性,但仍存在几个重要问题,包括饮酒与乳腺癌风险之间的关联是否受饮酒时间影响、是否会因体重指数(BMI)、绝经状态和激素替代疗法(HRT)等其他风险因素而改变,或者在激素受体阳性肿瘤或浸润性而非原位疾病中更为明显。
为解决这些问题,我们开展了一项基于人群的大型研究(1508例病例和1556例对照),收集了整个生命历程中关于饮酒及其他暴露因素的详细信息。
终生每天饮用15至30克(约一到两杯)酒与风险适度增加33%相关(比值比[OR]=1.33,95%置信区间[CI]=1.01 - 1.74),但饮酒量更大(每天≥30克)则不然。风险不因酒精类型(啤酒、葡萄酒或烈性酒)或饮酒模式(如近期饮酒、20岁前饮酒或是否早年开始饮酒)而有所不同。与终生饮酒量的关联仅限于BMI<25的女性(OR = 2.13,95%CI = 1.29 - 3.54)。对于BMI<25的女性,每天饮用约一杯酒与雌激素受体阳性肿瘤相关,但BMI≥25的女性则不然。此外,仅在诊断为浸润性乳腺癌的女性中观察到升高的OR(OR = 1.56,95%CI = 1.11 - 2.18),原位乳腺癌则未观察到。
这些数据进一步支持终生适度饮酒会增加乳腺癌风险,特别是在BMI较低的女性以及诊断为雌激素受体阳性肿瘤或浸润性而非原位疾病的女性中。风险仅限于适度饮酒量,且不因饮酒时间、饮酒量更大或所饮用酒精的类型而有所不同。